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ORIGINAL RESEARCH
Context: Women seem to be more vulnerable to dementia, particularly Alzheimer’s disease
(AD), than men. There is controversy among studies correlating estrogen deficit to cognitive
impairment. Because of the sudden drop of estrogens in menopause, this hormonal deficit
could represent one of the risk factors for the larger incidence and prevalence of AD in post-
menopausal women.
Rationale: We therefore wanted to find out if post-menopausal women with dementia, or
even in a prior stage, mild cognitive impairment (MCI), would have a more significant deficit
of estrogens than post-menopausal women without dementia, or any other type of cognitive
problem.
Objectives: The aim of this study was to detect possible differences of the sex hormone
levels among post-menopausal women, simultaneously affected by MCI or dementia, in
comparison with a control group without cognitive impairment.
Design, setting, and participants: A small, multicenter, prospective study was performed
on 82 post-menopausal women (41 cases, 41 controls), aged 45–81 years, to investigate their
sex hormone balance. The diagnosis of dementia was made according to ICD 9 or 10 and
DSM III-R or IV appropriate to the time interval. The diagnosis of probable AD followed the
NINCDS-ADRDA criteria. MCI met the Paquid-study criteria. Blood was analyzed in qualified
centers for LH, FSH, and 17-β-estradiol. All women went through a thorough psychiatric
examination and those with a suspected hormonal impairment were examined by a
gynecologist.
Results: 15 cases (36.6%) had impaired hormonal function, compared with 8 controls (19.5%).
Of the 15 cases with hormonal impairment, 9 had MCI.
Conclusions: These preliminary data stress a considerable difference between the sex hormone
status of these two populations, showing a tendency towards a more accentuated estrogen
deficit linked to cognitive deficit. Enlarging the sample and following the evolution could
bring more interesting data.
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Background
The intriguing fact that women are far more affected with Alzheimer’s disease (AD)
than men (Buckwalter et al 1993; Lamberts et al 1997; Hofman and Launer 1998;
Gelfand et al 2001) led us to think about risk factors specifically linked to gender
(Henderson 2000). Again women seem to have their own protective factors, which
give them a longer life expectancy then men, with a prevalence of 5%–7% more over
the age of 65 years and of up to 50% more over the age of 85 (Evans 1989; Jorm
1998). But what really differs between both genders are the sex hormones.
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There are several known risk factors other than gender
for AD (Snowdon 1997; Friedland 1998), namely, heredity,
old age, low level of education, and head injury, as well as
the disease risk modifier e4 allele for the apolipoprotein E
(ApoE).
The first clinical signs of the disease appear around
60–70 years, by the time women are already post-
menopausal. Men and women both produce estrogen, but
men do not suffer such an abrupt reduction of this hormone
as do women (Henderson 2000).
The timing of production of estrogens differs between
the two genders. Men start to produce testosterone in the
testicles between weeks 16 and 18 of fetal life. It migrates to
the brain to be aromatized into estrogen. And because there
is a regular and strong production of testosterone in the
normal male, estrogen quantities are also substantial in the
male brain, even more than in the female brain. Testosterone
production in men does not start to slow down until they
reach their eighties, by the time they just begin to be affected
by AD in the same proportion as women of their age.
Estrogens and progestagens are the main ovarian
steroids, although the ovaries produce also a small quantity
of the “male” testosterone.
During the normal menstrual cycle two gonadotropins
from the pituitary gland induce the production of estrogen
in the ovaries, by the luteinizing hormone (LH) in the thecal
cells and by the follicle stimulating hormone (FSH) in the
granulose cells. The most important circulating estrogen is
estradiol, which together with estrone and estriol builds the
main estrogens (Lobo 1999). Estradiol is transformed into
estrone by the liver and, as well as estrone, can convert into
the less active estriol.
Estrogens are derived from cholesterol via precursor
androgens: 17-β-estradiol, estrone, and estradiol. Estradiol
is the most important. Estradiol peaks prior to (in the
follicular phase) and after (in the luteal phase) ovulation. In
the luteal phase progesterone peaks, too.
The targets for estrogen are the reproductive tissues and,
more importantly, the brain (McEwen 1997), followed by
bone, vascular endothelium, and skin.
Testosterone converts into estradiol in neurons and in
astrocytes possessing the enzyme aromatase. It is through
large amounts of estrogen that the male fetus undergoes
masculinization.
Basic research shows that estrogens have a receptor
protein in the brain, which appears in two forms: α, mainly
in the hypothalamus, and β, throughout a great part of the
brain (Garcia-Segura 2003). They act in the neurons and in
the glia. In the hypothalamus they inhibit apoptosis; in the
glia they interact with a growth factor, insulin-like growth
factor 1 (IGF-1), to give neuroprotection after brain lesion.
They also decrease the expression of the levels of β-amyloid
in the brain of castrated female rats and in the plasma of
humans (Petanceska et al 2000; Almeida 2004).
Estrogens play a role in hippocampal neuronal long-term
potentiation, in reinforcing memory, and also act against
the effects of some memory-impairing drugs such as benzo-
diazepines and anticholinergics. They also have an action,
although apparently weak, in reducing the neuronal response
to oxidative stress (Cordoba 1997; Gibbs 1998; Sawada
1998), and improving regional cerebral blood flow (Ohkura
et al 1994; Belfort et al 1995). It is likely that the results of
animal studies on the correlation of endogenous estrogens
with cognitive performance do not agree with those on
humans (Daniel et al 1997; Packard and Teather 1997a,
1997b), in which the effect on cognitive variables such as
explicit memory and visual–spatial skills is very modest
(Polo-Kantola et al 1998; Resnick 1997). More than 50 years
of studies on humans have shown that menopausal estrogen
replacement therapy (ERT) enhances short- and long-term
memory and increases capacity for learning paired
associations but does not improve visual memory (Sherwin
1988, 1997).
There are also studies reporting the influence of
estrogens on the suppression of the activity of mono-
aminooxidase and on the increase of serotonin blood levels
in menopause (Luine and McEwen 1975; Gonzales and
Carrillo 1993).
Testosterone, but not estrogen, should also play a role.
Gelfand blocked the enzyme aromatase and found that
human primary neurons were protected by testosterone
through the androgen receptor (Gelfand et al 2001).
Menopause afflicts a large percentage of women with
hot flushes, day and night sweats, insomnia, vulvar and
vaginal dryness, fatigue, slowness, and forgetfulness, among
other symptoms. Excluding those women who already had
previous episodes of depression, there is usually no
depression in the sense of a psychiatric disease. Some
feelings of sadness or solitude are often reinforced by
preretirement, and or the so called “empty nest syndrome”,
and some women have also to face the burden of caring for
disabled parents.
Symptoms appear insidiously. Though the flushes are
different from usual, they often announce themselves by a
most discrete but sudden and unrelated sense of helplessness,
like an epileptic aura, almost always unnoticed, to beNeuropsychiatric Disease and Treatment 2006:2(2) 201
Hormone impairment in post-menopausal women
followed after approximately one minute by a crescendo
hot flush with unusual sweats. These are unusual because
they peculiarly start at less common sites, namely on the
lower legs, on the back of the knees, on the gluteal folds, on
the upper site of the forearms, and on the scalp, leaving the
body quite exhausted, accompanied by a uncomfortable
feeling of embarrassment. Since this may happen many
times in an hour, always out of control, concentration and
work rhythm tend to slow down, and soon an uncomfortable
sense of fatigue and irritation takes place. Such symptoms
begin to be treated by many gynecologists, psychiatrists,
and general physicians with serotonin reuptake inhibitors,
which often induce, or reinforce, loss of libido.
While the benefits of estrogens offer little evidence for
the treatment of an established dementia (Yaffe 2001), their
use as a preventive factor is still very controversial (Mulnard
et al 2000). Some authors suggest that in order to prevent
probable dementia, women must initiate hormone therapy
around menopause (Grodstein et al 2002; Resnick and
Henderson 2002).
By far the largest continuing study is the Women’s Health
Initiative (WHI) launched in 1991 to investigate the major
causes of death and disability for a period of 8–12 years, in
161 000 post-menopausal women (50–79 years), enrolled
between September 1993 and December 1998 in the US
(WHISG 1998; Fouad et al 2004). In the clinical trial arm,
27 347 women, aged 50–79 years, were assigned to the
hormone replacement component in 1996. From this section
the Women’s Health Initiative Memory Study (WHIMS) was
formed, enrolling more than 7500 women aged 65 or older,
without dementia. Part of the study (the combined hormone
therapy group, with a total of 2229 women randomized to
treatment with 0.625 mg/day of conjugated equine estrogen
plus 2.5 mg/day of medroxyprogesterone acetate or placebo)
was discontinued in 2002, 5.6 years after the start (less than
4 years before the planned end), because of increased risk
of breast cancer, heart disease, stroke, and venous
thromboembolism (Writing group for the WHI investigators
2002; Schneider 2004), despite showing decreased risks for
hip fracture and colon cancer.
The first WHIMS results (Shumaker et al 2003) reported
an increased risk of dementia with combined estrogen and
progestin therapy (Prempro™) without benefit for mild
cognitive impairment (MCI) or global cognition. Similar
adverse effects were reported by the Heart and Estrogen/
Progestin Replacement Study (HERS II) (Grady et al 2002;
Hulley et al 2002), and by the Million Women Study
(MWSC 2003).
The estrogen-alone group (3000 women) (Shumaker et
al 1998) went on for two more years to be stopped in
February 2004, because of increased risk for stroke
(decreased risk for hip fracture was also reported). The
results of the therapy were published as having an adverse
effect on cognition, an effect greater in women with initial
low cognitive levels (Espeland et al 2004; Schneider 2004).
Taking a critical look at these results (NIA), the risk of
dementia in the combined therapy group had no statistical
significance, the absolute risk being only 23 more cases per
10 000 women each year (12 extra cases of dementia for
each 10 000 women each year) (Shumaker et al 2003). In
other words, 40 out of 2229 women developed dementia
during the 5.6 years in the Prempro group while 21 out of
2303 women developed dementia in the placebo group
during the same period (Alzheimer’s Association 2003).
Also the differences between the estrogen-alone and the
placebo groups of WHIMS, although statistically significant,
were not considered clinically relevant for overall cognitive
abilities. The increased risk of dementia was not statistically
significant (Rapp et al 2003; Shumaker et al 2003; Espeland
et al 2004). Another criticism was that the findings could be
different for lower doses or other types of hormone replace-
ment therapy (HRT) (Editorials BMJ 2002). In fact, the US
Food and Drug Administration (FDA) approved in March
2003 a lower daily dose tablet of Prempro (0.45 mg estrogens
instead of 0.625 mg and 1.5 mg progestin instead of 2.5 mg)
for the specific symptoms of menopause in women with
uterus (because progestin lowers the risk of having uterine
problems), but not recommending its use for the prevention
of heart disease, heart attacks, or strokes (FDA 2003).
It should be noted that for a white, caucasian woman
the estimated cumulative absolute risk of death between the
ages of 50 and 94 years is 31% from coronary heart disease,
2.8% from breast cancer, and 2.8% from hip fracture
(Brinton and Schairer 1997).
A meta-analysis showed that the increased risk of breast
cancer affects only women who consume alcohol (5 g or
more daily) along with estrogen (Longnecker et al 1988;
Colditz et al 1990; Gapstur et al 1992). In a post-menopausal
woman who drinks alcohol, the blood level of estradiol goes
up by about 300% (Ginsburg et al 1996).
Most women enrolled in WHIMS were much too old
for a post-menopausal hormonal study (Schneider 2004).
Some women had also already taken hormones, and the
possibility remains that some women who were described
as having developed MCI or dementia during the trial
already had it, subclinically, at the start point.Neuropsychiatric Disease and Treatment 2006:2(2) 202
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Based on the WHIMS results, NIA recommended in
March 2004 that either estrogens alone or combined with
progestin should be prescribed for older women to maintain
or improve cognitive function, not directly addressing
decisions about the short term use of combination therapy
by younger women to relieve symptoms of menopause
(NHLBI 2004; WHI 2004).
Other trials found similar results to those of WHIMS for
the cognition (Henderson 2000; Mulnard et al 2000; Wang
et al 2000). There is evidence for and against the effects of
estrogen on cognition being dose- and age-related (Yaffe et
al 1998b; Le Blanc et al 2001; Geerlings et al 2003; Almeida
and Flicker 2005). A few studies report a protective action
against developing AD, probably as a dose-related phenomenon
(Tang et al 1996; Kawas et al 1997; Lerner et al 1997).
The Alzheimer’s Association also expressed a sceptical
opinion, considering the actual individual risk for dementia
in the WHIMS study very small and reinforcing that age
would still be the major individual risk factor for dementia
(Albert 2003).
Before WHIMS was launched there were already other
robust studies. The Baltimore Longitudinal Study (Kawas
et al 1997) reported a 54% reduced risk for AD among post-
menopausal women who had ever taken ERT. Paganini-Hill
et al (1994), who conducted by far the largest ERT study
before WHI, found that retired women who also had ever
taken ERT developed one third less AD.
In a perimenopausal follow-up of 5 years, Tang et al
(1996) found that those women who were already on ERT
had a decrease of 50% in developing AD.
But in a group of women already with mild to moderate
AD, some on unopposed estrogens and some on combined
hormones, the estrogen-alone subgroup showed cognitive
decline and the combined therapy group failed to present
cognitive benefits (Mulnard et al 2000).
All these results are in favor of an action of HRT for
menopause more as a factor of prevention or protection for
AD or related dementias rather than a therapy once the
disease is established.
Methods
The study was conducted simultaneously in three different
centers by a geriatric psychiatrist with extensive experience
in dementia, namely in the outpatient clinic for demented
patients at a university hospital (neurology department); in
the psychogeriatric sector of a clinical center, and in one
community medical center (general practice and women
health sectors), all in the same locality.
The study sample consisted of community-dwelling
women who came to their regular appointments and
consented to be enrolled. Out of 133 screened women, 13
did not meet the criteria and 38 were excluded because of
dropout or other reasons. Exclusion criteria for cases and
controls were psychiatric or physically significant diseases,
such as depression, epilepsy, cancer, stroke, uncontrolled
hypertension, diabetes, thyroid disease, or any other
significant metabolic disorder or serious disease (all women
had recently been to their family physician), as well as
current or previous treatment with HRT or anti-
cholinesterases.
All women went through a thorough psychiatric
examination by one and the same psychiatrist with
considerable experience in dementia, and were screened
using the Mini Mental State Examination (MMSE) (Folstein
et al 1975), validated for the Portuguese population, and/or
the Information-Memory-Concentration Test (Blessed et al
1968); the Global Deterioration Scale (GDS) (Reisberg et
al 1982); the Blessed Dementia Scale (Blessed et al 1968);
Hamilton scales for depression (Hamilton 1960) and for
anxiety (Hamilton 1969); and the Hachinski ischemic scale
(Hachinski et al 1975). Cut off points of the Portuguese-
validated MMSE are: ≤ 15 for illiterate, ≤ 22 for those with
1–11 years of school education, and ≤ 27 for those with more
than 11 years of school education.
A sex hormone profile was requested from all women,
to be performed in highly qualified laboratories. Required
was: 17-β-estradiol, FSH, LH, and prolactin. The main
laboratory criteria for menopause (chemoluminescence
method) were: FSH: 25.0–145 mUI/mL; 17-β-estradiol
< 30 pg/mL; and LH 18.0–65.0 mUI/mL. 17-β-estradiol is
the considered the more important estrogen in this context
(Lobo 1999).
Only cases were included who met the criteria for
dementia according to DSM-III R or DSM-IV (APA 1987,
1994), or ICD-9 or ICD-10 (WHO 1975, 1992), depending
on the time interval; for AD according to the ADRDA-
NINCDS (McKhann et al 1984); and for MCI according to
the Paquid study criteria (Dartigues et al 1991a, 1991b,
1992; Barberger-Gateau et al 1992, 1993). GDS scores were
2–7 for cases (mild cognitively impaired to moderate/
severely demented), and MMSE according to the above-
mentioned cut-off points. Controls GDS scores were 1–2.
Cases underwent a structured interview in the context
of the regular psychiatry–psychogeriatric appointment, some
of them with help of the caregiver. Each case with
menopausal symptoms and biochemical hormone deficitNeuropsychiatric Disease and Treatment 2006:2(2) 203
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agreed to be evaluated and examined by a gynecologist,
who performed a gynecological observation, requested
mammography and mammary ultrasound, and carried out
the pap cell test. After having met the clinical diagnosis of
estrogen deficit, the gynecologist informed the women, in
the indicated cases, on the risks and advantages of HRT.
Controls without any cognitive impairment were all
selected either from medicine (general practice) or
gynecology. Forty-one cases and 41 controls were enrolled
between 1994 and 1998, aged 42–87 years, mean 63.8 years,
more exactly 67.4 years for the cases (45–87 years) and
60.3 years for the controls (42–79 years) (Table 1).
Results
Among the cases the following diagnoses were found. MCI:
15 cases = 36.5%; AD: 11 cases = 26.8%; uncharacterized
dementia (DEM): 10 cases = 24.3%, frontal dementia (FD):
2 cases = 4.8%; vascular dementia (VD): 1 case = 2.4%;
Parkinson’s dementia (PD): 1 case = 2.4%; alcohol dementia
(AlcD): 1 = 2.4% (Table 2).
Most of the cases belonged to MCI, AD, and DEM. MCI
with a mean age of 63.8 was the youngest group. It would
obviously be interesting to know how these MCI and DEM
cases would be later distributed, as the disease progresses
and the diagnosis becomes more clear.
According to the conclusions of the gynecologist, there
were 15 cases with estrogen deficit (36.6%) compared with
only 8 controls (19.5%) (Table 3). The distribution of these
cases with hormonal impairment was: MCI, 21.9%; DEM,
7.3%; AD, 4.8%; AlcD, 2.4% (Table 3).
Most of the cases with estrogen deficit were from the
MCI subgroup (9 cases), far more significant than the DEM
(3 cases) and AD (2 cases) subgroups. There is evidence
from other studies that half or more of these MCI cases
decline within few years to AD or related dementia, but a
considerable percentage does revert to normal, or near
normal, again (Rubin et al 1989; Flicker et al 1991; Ritchie
et al 2000).
Discussion
The results of the present study provide evidence for a
tendency for menopausal women with estrogen deficit to
present an impairment of cognitive function in the form of
MCI or dementia, particularly compared with the controls
(36.6%–19.5%), which is in keeping with our initial
hypothesis that an estrogen deficit could be a risk factor for
AD or even for some other types of dementia.
Our study, although original, has some limitations. It
was much too small to be a case control study, had a great
disparity of ages, and lacked any other suitable factor (like
level of education) that would allow us to match cases with
controls (Table 4). It may well be considered that once
menopause begins age does not play such an important role
in what concerns sex hormone level, and so the age
differences would not be important.
The enrolment should also have been bilateral, not
mainly from psychiatry–psychogeriatry but from
gynecology, too, which happened only with two women.
All women should have been checked by a second
experienced psychiatrist or neurologist.
We conclude that elderly women with MCI and dementia
tend to show a significant estrogen deficit, particularly when
compared with cognitively unimpaired controls. An estrogen
deficit may represent an important risk factor for MCI, AD,
and even some other types of dementia.
Table 1 Average age of controls and cases
Average age
(years) MCI DEM AD
Controls (n = 41) (42–79) 60.3
Cases (n = 41) (45–87) 67.4 63.8 71.2 69.8
Abbreviations: AD, Alzheimer’s disease; DEM, undiagnosed dementia; MCI, mild
cognitive impairment.
Table 2 Diagnosis of cases (n = 41)
Diagnosis n (%)
MCI 15 (36.5%) 
AD 11 (26.8%)
DEM 10 (24.3%)
FD 2 (4.8%)
VD 1 (2.4%)
PD 1 (2.4%)
AlcD 1 (2.4%)
Abbreviations: AD, Alzheimer’s disease; AlcD, alcohol dementia; DEM,
undiagnosed dementia; MCI, mild cognitive impairment; FD, frontal dementia; VD,
vascular dementia; PD, Parkinson’s dementia.
Table 3 Women with hormonal deficit
With hormonal
impairment
Controls (n=41) 8 (19.5%)
Cases (n=41) 15 (36.6%)
MCI 9 (21.9%)
DEM 3 (7.3%)
AD 2 (4.8%)
AlcD 1 (2.4%)
Abbreviations: AD, Alzheimer’s disease; AlcD, alcohol dementia;
DEM, undiagnosed dementia; MCI, mild cognitive impairment.Neuropsychiatric Disease and Treatment 2006:2(2) 204
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Table 4 Stratification by age of cases and controls with respective pathology and hormonal impairment
Nr cases % cases Nr controls % controls
with HI with HI with HI with HI
per age per age per age per age
Cases/Age Pathology HI  decile decile Controls/age HI decile decile
45 MCI 1 42 0
47 MCI 0 46 0
51 MCI 1 47 0
54 MCI 1 47 1
55 MCI 1 48 0
57 AD 0 48 0 8 16.66
59 DEM 0 50 1
59 AD 0 4 50 50 0
60 MCI 1 51 1
60 AlcD 1 51 1
60 DEM 0 53 0
60 DEM 0 54 0
61 MCI 0 54 0
61 FD 0 54 0
63 MCI 0 55 0
64 VD 0 57 0
65 AD 1 58 0
66 AD 0 59 0 3 25
67 MCI 1 62 0
67 AD 0 62 1
69 PD 0 63 0
69 MCI 0 4 28.57 64 0
70 DEM 0 64 0
72 MCI 0 64 1
72 AD 1 64 0
73 AD 0 65 0
73 MCI 1 65 0
74 DEM 1 65 1
74 AD 0 67 0
75 AD 0 67 0
75 MCI 1 67 1
76 FD 0 68 0
76 DEM 0 68 0 4 26.66
77 DEM 1 70 0
78 MCI 0 71 0
78 DEM 0 72 0
78 DEM 0 72 0
79 AD 0 75 0
80 DEM 1 76 0
81 AD 0 77 0
87 MCI 1 7 36.84 79 0 0 0
Total with HI 15 8
% total with HI 36.58 19.51
Abbreviations: AD, Alzheimer’s disease; AlcD, alcohol dementia; DEM, undiagnosed dementia; MCI, mild cognitive impairment; FD, frontal dementia; HI, hormonal
impairment; PD, Parkinson’s disease; VD, vascular dementia.Neuropsychiatric Disease and Treatment 2006:2(2) 205
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